Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety

References

• American Psychiatric Association. 1998. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 155:1–34.
   Web of Science ®Google Scholar
• Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S. 2013. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol (Oxford). 27:967–971.
   PubMed Web of Science ®Google Scholar
• Balon R, Fava GF, Rickels K. 2015. Need for a realistic appraisal of benzodiazepines. World Psychiatry. 14:243–244.
   PubMed Web of Science ®Google Scholar
• Bachhuber MA, Hennessy S, Cunningham CO, Starrel JL. 2016. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 106:686–688.
   PubMed Web of Science ®Google Scholar
• Balter MB, Levine J, Manheimer DI. 1974. Cross-national study of the extent of anti-anxiety-sedative drug use. N Engl J Med. 290:769–774.
   PubMed Web of Science ®Google Scholar
• Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, Keller MB. 2003. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 160:1432–1438.
   PubMed Web of Science ®Google Scholar
• Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora A. 1986. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 315: 854–859.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. 2016. The safety, tolerability and risk associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 85:270–288.
   PubMed Web of Science ®Google Scholar
• Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G. 2015. Hypnotics and triazolobenzodiazepines - best predictors of high-dose benzodiazepine use: results from the luxembourg national health insurance registry. Psychother Psychosom. 84:273–283.
   PubMed Web of Science ®Google Scholar
• Cross-National Collaborative Panic Study Investigators 1992. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, 2nd Phase. Br J Psychiatry. 160:191–202.
   PubMed Web of Science ®Google Scholar
• Fava GA, Balon R, Rickels K. 2015. Benzodiazepines in anxiety disorders. JAMA Psychiatry. 72:733–734.
   PubMed Web of Science ®Google Scholar
• Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. 2015. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 84:72–81.
   PubMed Web of Science ®Google Scholar
• Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R. 2009. Clinical evaluation of the daily assessment of symptoms-anxiety (DAS-S): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. CNS Neurosci Ther. 15:12–18.
   PubMed Web of Science ®Google Scholar
• Freire RC, Amrein R, Mochcovitch MD, Dias GL, Machado S, Versiani M, Arias-Carrion O, Carta MG, Nardi AE. 2017. A 6-year posttreatment follow-up of panic disorder patients: treatment with clonazepam predicts lower recurrence than treatment with paroxetine . J Clin Psychopharmacol. 37:429–434.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. 2013. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI stydies. Biobehav Rev. 37:1680–1691.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. 2018. Update on psychotropic drug prescribing in the United States 2014-2015. J Clin Psychopharmacol. 31:1–3.
   Google Scholar
• Greenblatt DJ, Shader RI, Abernethy DR. 1983. Current status of benzodiazepines. N Eng J Med. 309:410–416.
   PubMed Web of Science ®Google Scholar
• Hacket D, Haudiquet V, Salinas E. 2003. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalized anxiety disorder. Eur Psychiatry.18:182–187.
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod DR, Zimmerli WD. 1988. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry. 49:293–301.
   PubMed Web of Science ®Google Scholar
• IMS Health. 2007. IMS National Prescription audit 01/2007 – 12/2007, extracted February 2008.
   Google Scholar
• Kahn RJ, McNair DM, Lipman RS. 1986. Imipramine and chlordiazepoxide in depressive and anxiety disorders II. Efficacy in anxious outpatients. Arch Gen Psychiatry. 43:79–85.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Stossel S, Krystal AD. 2015. Restricting benzodiazepines to short-term prescription. JAMA Psychiatry. 72:734–735.
   PubMed Web of Science ®Google Scholar
• Maust DT, Blow FC, Wiechers IR, Kales HC, Marcus SC. 2017. Antidepressant, benzodiazepine, and other sedative-hypnotic treatment of older adults in psychiatric and primary care. J Clin Psychiatry. 78:e363–e371.
   PubMed Web of Science ®Google Scholar
• Mellinger GD, Balter MB, Uhlenhuth EH. 1984. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA. 251:375–379.
   PubMed Web of Science ®Google Scholar
• Möller HJ, Volz HP, Reimann IW, Stoll KD. 2001. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 21:59–65.
   PubMed Web of Science ®Google Scholar
• Moore N, Pariente A, Begaud B. 2015. Why are benzodiazepines not yet controlled substances? Jama Psychiatry. 72:110–111.
   PubMed Web of Science ®Google Scholar
• Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valença AM, Veras AB, Paes F, Sardinha A. 2012. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 32:120–126.
   PubMed Web of Science ®Google Scholar
• Nardi AE, Valença AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, et al. 2011. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 44:366–373.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Hansen EH, Gotzsche PC. 2012. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 107:900–908.
   PubMed Web of Science ®Google Scholar
• O’Brien CP. 2005. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 66:28–33.
   PubMed Web of Science ®Google Scholar
• Offidani E, Guidi J, Tomba E, Fava GA. 2013. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 82:355–362.
   PubMed Web of Science ®Google Scholar
• Olfson M, King M, Schoenbaum M. 2015. Benzodiazepine Use in the United States. JAMA Psychiatry. 72:136–142.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, Stein MB. 2014. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. AJP Psychiatry. 171:44–53.
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Rickels K. 2015. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opinion Pharmacother. 16:1669–1681.
   PubMed Web of Science ®Google Scholar
• Rickels K. 2013. Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom. 82:351–352.
   PubMed Web of Science ®Google Scholar
• Rickels K, DeMartinis N, Garcia-Espana F, Greenblatt D, Mandos L, Rynn M. 2000a. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long- term benzodiazepine therapy. AJP Psychiatry. 157:1973–1979.
   PubMed Web of Science ®Google Scholar
• Rickels K, DeMartinis N, Rynn M, Mandos L. 1999. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 19:12S–16S.
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. 1993. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 50:884–895.
   PubMed Web of Science ®Google Scholar
• Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. 2010. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 67:1274–1281.
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000b. Efficacy of extended-release Venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 157:968–974.
   PubMed Web of Science ®Google Scholar
• Rickels K, Rynn M. 2002. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 63:9–16.
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. 1988. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 45:444–450.
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Lucki I. 1987. Benzodiazepine side effects. American Psychiatric Association Annual Review, Vol 6. Hales RE and Francis AJ editors. Washington: American Psychiatric Press, Inc; pp 781–801.
   Google Scholar
• Rickels K, Zaninelli R, McCafferty J, Bellew J, Iyengar M, Sheehan D. 2003. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 160:749–756.
   PubMed Web of Science ®Google Scholar
• Roy-Byrne P. 2014. Treatment in nonresponsive patients with social anxiety disorder: Back to the future with benzodiazepines. Am J Psychiatry. 171:1–4.
   PubMed Web of Science ®Google Scholar
• Salzman C. 1990. Benzodiazepine dependency, toxicity and abuse. Washington, DC: American Psychiatric Association.
   Google Scholar
• Salzman C, Shader RI. 2015a. Benzodiazepine use and risk for Alzheimer disease. J Clin Psychopharmacol. 35:1–3.
   PubMed Web of Science ®Google Scholar
• Salzman C, Shader RI. 2015b. Not again: Benzodiazepines once more under attack. J Clin Psychopharmacol. 35:493–495.
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, De Martinis N, Case G, García-España F. 1998. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med. 28:713–720.
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Weiss S, Zavodnick S. 1993. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 50:51–60.
   PubMed Web of Science ®Google Scholar
• Soyka M. 2017. Treatment of benzodiazepine dependence. N Engl J Med. 376:1147–1157.
   PubMed Web of Science ®Google Scholar
• Stahl SM. 2002. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 63:756–757.
   PubMed Web of Science ®Google Scholar
• Starcevic V. 2014. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 14:1275–1286.
   PubMed Web of Science ®Google Scholar
• Starcevic V. 2015. The popularity of benzodiazepines, their advantages, and inadequate pharmacological alternatives. JAMA Psychiatry. 72:623–624.
   PubMed Web of Science ®Google Scholar
• Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. 2013. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 62:3232–3240.
   PubMed Web of Science ®Google Scholar
• Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. 2005. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety. 22:59–67.
   PubMed Web of Science ®Google Scholar
• Winokur A, Rickels K, Greenblatt DJ, Snyder PJ, Schatz NJ. 1980. Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. Arch Gen Psychiatry. 37:101–105.
   PubMed Web of Science ®Google Scholar
• Zito JM. 2015. High-dose benzodiazepine use among long-term users: when will we ever learn? Psychother Psychosom. 84:259–261.
   PubMed Web of Science ®Google Scholar